torcetrapib has been researched along with anacetrapib in 42 studies
| Studies (torcetrapib) | Trials (torcetrapib) | Recent Studies (post-2010) (torcetrapib) | Studies (anacetrapib) | Trials (anacetrapib) | Recent Studies (post-2010) (anacetrapib) |
|---|---|---|---|---|---|
| 273 | 28 | 83 | 179 | 33 | 143 |
| Protein | Taxonomy | torcetrapib (IC50) | anacetrapib (IC50) |
|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | 0.0343 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (16.67) | 29.6817 |
| 2010's | 33 (78.57) | 24.3611 |
| 2020's | 2 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Beyer, TP; Borel, A; Cannady, EA; Cao, G; Cockerham, SL; Escribano, A; Fernandez, MC; Frank, S; Jones, TM; Mantlo, NB; Martin de la Nava, EM; Mateo, AI; Parthasarathy, S; Schmidt, RJ; Stephenson, G; Sweetana, SA; Wang, X; Zhang, Y | 1 |
| Berta, D; Cremonesi, P; Fuchs, K; Hamprecht, D; Luippold, G; Markert, M; Nar, H; Streicher, R; Trieselmann, T; Volz, A; Wagner, H | 1 |
| Cao, G; Chang, Y; Chen, D; He, X; Huang, X; Liu, J; Luo, H; Ni, S; Shen, Q; Sun, H; Wang, P; Wen, X; Zhou, H | 1 |
| Brousseau, M; Honma, W; Iimura, A; Imase, H; Iwaki, Y; Kawanami, T; LaSala, D; Liang, G; Mitani, H; Mogi, M; Nonomura, K; Ohmori, O; Pan, M; Rigel, DF; Umemura, I; Yamada, K; Yasoshima, K; Zhu, G | 1 |
| Amin, RP; Bao, J; Blaustein, RO; Campeau, LC; Chen, Q; Chen, YH; Cote, J; Duffy, JL; Hartmann, G; Johns, DG; Katipally, R; Leung, D; Lipardi, C; Liu, G; Liu, J; Lu, Z; Metzger, D; Mitra, K; Murphy, BA; Ondeyka, D; Shao, PP; Sinclair, PJ; Sun, W; Tan, L; Tyagarajan, S; Vachal, P; Wang, SP; Wollenberg, GK; Xu, Y; Ye, F; Zhao, K | 1 |
| Duriez, P | 1 |
| Hegele, RA; Joy, TR | 1 |
| Bloomfield, D; Briscoe, RJ; Brown, PN; Cumiskey, AM; Ehrhart, J; Forrest, MJ; Hershey, JC; Keller, WJ; Ma, X; McPherson, HE; Messina, E; Peterson, LB; Sharif-Rodriguez, W; Siegl, PK; Sinclair, PJ; Sparrow, CP; Stevenson, AS; Sun, SY; Tsai, C; Vargas, H; Walker, M; West, SH; White, V; Woltmann, RF | 1 |
| Hegele, RA; Joy, T | 1 |
| Masterjohn, C | 1 |
| Shinkai, H | 2 |
| Stroes, ES; Vergeer, M | 1 |
| Böhm, M; Laufs, U; Pöss, J | 1 |
| Addona, G; Bierilo, KK; Chen, Q; Chen, Y; Elowe, NH; Eveland, S; Fisher, TS; Frantz-Wattley, B; Garcia-Calvo, M; Houde, C; Hubbard, B; Kavana, M; Koblan, KS; Milot, D; O'Neill, EA; Porter, G; Ranalletta, M; Sinclair, P; Sitlani, A; Sparrow, C; Tung, E | 1 |
| Hausenloy, DJ; Opie, L; Yellon, DM | 1 |
| Blum-Kaelin, D; Chaput, E; Clerc, RG; Dernick, G; Huber, W; Kakutani, M; Magg, C; Matile, H; Maugeais, C; Niesor, EJ; Ogawa, N; Okamoto, H; Pflieger, P; Schmid, G; Takahashi, D; Thoma, R; von der Mark, E | 1 |
| Katsnelson, A | 1 |
| Athyros, VG; Katsiki, N; Mikhailidis, DP | 1 |
| Devaraj, S; Jialal, I | 1 |
| Niesor, EJ | 1 |
| Ghosh, RK; Ghosh, SM | 1 |
| Fisher, EA; Hewing, B | 1 |
| Deanfield, J; Kastelein, J; Landmesser, U; Lüscher, TF; von Eckardstein, A | 1 |
| Duivenvoorden, R; Fayad, ZA | 1 |
| Akhlaghi, F; Mohammadpour, AH | 1 |
| Cai, J; Chen, C; Hu, Z; Li, C; Li, Y; Liu, L; Luo, H; Pei, F; Zeng, C; Zhang, W; Zhou, F; Zhou, L | 1 |
| deGoma, EM; Rader, DJ | 1 |
| Francis, DP; Keene, D; Price, C; Shun-Shin, MJ | 1 |
| McCullough, PA; Shin, HJ | 1 |
| Even, S; Montezano, AC; Neves, KB; Nguyen Dinh Cat, A; Palacios, R; Rios, FJ; Touyz, RM | 1 |
| Barter, PJ; Kastelein, JJ; Nicholls, SJ; Rye, KA | 1 |
| Boekholdt, SM; Hovingh, GK; Ray, KK | 1 |
| Quintão, EC | 1 |
| Barkas, F; Elisaf, M; Filippatos, TD; Klouras, E | 1 |
| Avorn, J; Franklin, JM; Hey, SP; Kesselheim, AS | 1 |
| Cao, Y; Hao, D; Yang, Z; Yuan, X; Zhang, L; Zhang, S | 1 |
| Charles, MA; Johns, DG; Krauss, RM; Lei, D; Peng, B; Ren, G; Rye, KA; Yang, M; Zhang, L; Zhang, M | 1 |
| Corsini, A; Macchi, C; Matsuzawa, Y; Ruscica, M; Sirtori, CR; Yamashita, S | 1 |
| Ahsan, M; Dixit, SM; Senapati, S | 1 |
| Bis, JC; Charoen, P; Chaturvedi, N; Drenos, F; Finan, C; Franceschini, N; Gaunt, TR; Giambartolomei, C; Gordillo-Marañón, M; Hingorani, AD; Hughes, AD; Hunt, NB; Kivimaki, M; Lawlor, DA; Mook-Kanamori, DO; O'Donnell, CJ; Papacosta, O; Price, JF; Schmidt, AF; Sofat, R; Wannamethee, G; Wong, A; Zwierzyna, M | 1 |
18 review(s) available for torcetrapib and anacetrapib
| Article | Year |
|---|---|
The end of the road for CETP inhibitors after torcetrapib?
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2009 |
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Topics: Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Esters; Humans; Oxazolidinones; Patents as Topic; Quinolines; Sulfhydryl Compounds | 2009 |
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Topics: Aldosterone; Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Corticosterone; Esters; Humans; Hydrocortisone; Hypercholesterolemia; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2009 |
[HDL and CETP in atherogenesis].
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Nicotinic Acids; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome | 2010 |
Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Esters; Humans; Lipoproteins, HDL; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2011 |
Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Hyperlipidemias; Oxazolidinones; Quinolines; Risk Factors; Sulfhydryl Compounds | 2012 |
Rationale for cholesteryl ester transfer protein inhibition.
Topics: Amides; Animals; Benzodiazepines; Cholesterol Ester Transfer Proteins; Drug Discovery; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2012 |
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Topics: Amides; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Esters; Humans; Hypolipidemic Agents; Oxazolidinones; Quinolines; Sulfhydryl Compounds; Treatment Outcome | 2012 |
Safety of CETP inhibition.
Topics: Amides; Animals; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Oxazolidinones; Quinolines; Safety; Sulfhydryl Compounds | 2012 |
Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
Topics: Adult; Amides; Anticholesteremic Agents; Benzodiazepines; Blood Pressure; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome; Triglycerides | 2013 |
Future of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2014 |
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Myocardial Infarction; Niacin; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Stroke; Sulfhydryl Compounds | 2014 |
Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Topics: Amides; Apolipoprotein A-I; Benzodiazepines; Black or African American; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Esters; Heart Diseases; Humans; Hyperlipoproteinemias; Kidney Diseases; Liver; Niacin; Observational Studies as Topic; Oxazolidinones; Prospective Studies; Quinolines; Randomized Controlled Trials as Topic; Risk; Sulfhydryl Compounds; Triglycerides; White People | 2014 |
The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
Topics: Amides; Animals; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Hypercholesterolemia; Mice; Oxazolidinones; Quinolines; Rabbits; Sulfhydryl Compounds | 2016 |
Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Esters; Humans; Lipids; Lipoprotein(a); Lipoproteins, HDL; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2016 |
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Biomarkers, Pharmacological; Cholesterol Ester Transfer Proteins; Drug Approval; Drug Discovery; Dyslipidemias; Endpoint Determination; Esters; Humans; Lipids; Oxazolidinones; Predictive Value of Tests; Quinolines; Reproducibility of Results; Sulfhydryl Compounds; Time Factors; Treatment Outcome | 2017 |
Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Lignans; Lipoproteins, HDL; Lipoproteins, VLDL; Oxazolidinones; Probucol; Quinolines; Sulfhydryl Compounds; Triglycerides | 2018 |
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Humans; Mendelian Randomization Analysis; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2021 |
24 other study(ies) available for torcetrapib and anacetrapib
| Article | Year |
|---|---|
Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Topics: Animals; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Dose-Response Relationship, Drug; Drug Design; Humans; Inhibitory Concentration 50; Mice; Naphthyridines; Structure-Activity Relationship | 2012 |
Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Hydroxyquinolines; Macaca fascicularis; Mice, Transgenic; Quinolines; Spiro Compounds; Structure-Activity Relationship | 2014 |
Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.
Topics: Animals; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Drug Discovery; Esters; Guinea Pigs; Humans; Mice; Mice, Transgenic; Molecular Structure; Structure-Activity Relationship; Triterpenes | 2017 |
Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma.
Topics: Aged; Animals; Chick Embryo; Cholesterol Ester Transfer Proteins; Humans; Hypertriglyceridemia; Male; Mesocricetus; Piperidines; Rats; Structure-Activity Relationship | 2017 |
Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Dogs; Humans; Macaca mulatta; Mice, Inbred C57BL; Molecular Structure; Oxazolidinones; Rats, Wistar; Structure-Activity Relationship | 2021 |
Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Heart Diseases; Humans; Oxazolidinones; Quinolines; Risk Factors | 2008 |
The failure of torcetrapib: what have we learned?
Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Humans; Hyperaldosteronism; Oxazolidinones; Quinolines | 2008 |
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.
Topics: Adrenal Cortex; Aldosterone; Animals; Anticholesteremic Agents; Blood Pressure; Cholesterol Ester Transfer Proteins; Corticosterone; Dogs; Drug Evaluation, Preclinical; Female; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Models, Animal; Muscle, Smooth, Vascular; Oxazolidinones; Quinolines; Rats; Rats, Sprague-Dawley; Species Specificity | 2008 |
Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Endothelium, Vascular; Humans; Hypercholesterolemia; Oxazolidinones; Quinolines; Treatment Outcome; Triglycerides; Vitamin E | 2009 |
Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Animals; Anticholesteremic Agents; Blood Proteins; Cholesterol Ester Transfer Proteins; Esters; Humans; Mice; Molecular Structure; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2010 |
Dissociating HDL cholesterol from cardiovascular risk.
Topics: Amides; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Predictive Value of Tests; Primary Prevention; Quinolines; Risk Assessment; Risk Factors; Secondary Prevention; Sulfhydryl Compounds | 2010 |
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Topics: Amides; Animals; Anticholesteremic Agents; Bile Acids and Salts; Binding Sites; Biological Transport; Cholesterol; Cholesterol Ester Transfer Proteins; Cricetinae; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Esters; High-Density Lipoproteins, Pre-beta; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2010 |
Good news for 'good' cholesterol.
Topics: Amides; C-Reactive Protein; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Esters; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2010 |
Trial watch: hope renewed for strategy to raise HDL cholesterol.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Dyslipidemias; Humans; Oxazolidinones; Quinolines; Risk Factors | 2011 |
The DEFINE study: a bright future for CETP inhibitors?
Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Oxazolidinones; Quinolines | 2011 |
Novel cholesteryl ester transfer protein inhibitors: promising therapy for dyslipidemia?
Topics: Cholesterol Ester Transfer Proteins; Drugs, Investigational; Dyslipidemias; Humans; Hypolipidemic Agents; Molecular Targeted Therapy; Oxazolidinones; Quinolines | 2011 |
Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
Topics: Acute Coronary Syndrome; Amides; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Early Termination of Clinical Trials; Esters; Humans; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds | 2012 |
Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2013 |
Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
Topics: Adipocytes; Aldosterone; Amides; Animals; Cell Line; Cholesterol Ester Transfer Proteins; Esters; Humans; Mice; NADPH Oxidases; Oxazolidinones; Phosphorylation; Quinolines; Reactive Oxygen Species; STAT3 Transcription Factor; Sulfhydryl Compounds | 2015 |
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome | 2015 |
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome | 2015 |
Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback.
Topics: Anticholesteremic Agents; Benzodiazepines; Binding Sites; Cholesterol Ester Transfer Proteins; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxazolidinones; Protein Binding; Protein Structure, Secondary; Quinolines; Solvents; Thermodynamics | 2018 |
Assessing the mechanisms of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Cholesterol Ester Transfer Proteins; Esters; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Multiprotein Complexes; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2017 |
Steering the Lipid Transfer To Unravel the Mechanism of Cholesteryl Ester Transfer Protein Inhibition.
Topics: Binding Sites; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Humans; Hydrophobic and Hydrophilic Interactions; Lipoproteins, HDL; Lipoproteins, LDL; Molecular Dynamics Simulation; Oxazolidinones; Protein Binding; Protein Conformation; Quinolines | 2019 |